Welcome to the SPIRIT 2 website STI571 Prospective International RandomIsed Trial 2 A phase III, prospective randomised comparison of -imatinib (STI571, Glivec/Gleevec) 400mg daily versus - dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia
Closed to recruitment : March 2013 Last patient last visit : March 2018